Lipocine announces positive week 52 results from lpcn 1148 phase 2 study in patients with cirrhosis

Met primary and hepatic encephalopathy (he) endpoints in phase 2 study increase in skeletal muscle index (smi) observed at week 24 was maintained through 52 weeks participants on placebo increased smi when switched to lpcn 1148 fewer overt hepatic encephalopathy (ohe) events and time to first recurrent ohe event was longer while on lpcn 1148 therapy lpcn 1148 was well-tolerated, with ae rates and severities similar to placebo. participants on lpcn 1148 were hospitalized for fewer days salt lake city , march 28, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company today announced positive topline results from a phase 2 clinical study of lpcn 1148.
LPCN Ratings Summary
LPCN Quant Ranking